← Back to Clinical Trials
Recruiting NCT07502456

NCT07502456 Clareon TruPlus Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07502456
Status Recruiting
Phase
Sponsor Alcon Research
Condition Aphakia
Study Type INTERVENTIONAL
Enrollment 122 participants
Start Date 2026-05-26
Primary Completion 2028-06

Eligibility & Interventions

Sex All sexes
Min Age 22 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Clareon TruPlus Monofocal Non-Toric IOLClareon TruPlus Monofocal Toric IOLPhacoemulsification

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 122 participants in total. It began in 2026-05-26 with a primary completion date of 2028-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this research study is to generate safety and performance data for Clareon TruPlus Monofocal Intraocular Lenses (IOLs). IOLs are medical devices that are implanted in the eye during cataract surgery to restore clear vision after the cloudy natural lens has been removed. IOLs are intended to remain in the eyes for the duration of the patient's lifetime.

Eligibility Criteria

Key Inclusion Criteria: * Diagnosed with bilateral cataracts and planned bilateral cataract extraction by routine phacoemulsification. * Potential postoperative BCDVA of 0.2 logMAR or better in each eye in the expert medical opinion of the investigator. * Astigmatism suitable for correction with available toric IOL models. * Other protocol-specified inclusion criteria may apply. Key Exclusion Criteria: * Age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, and other eye conditions as specified in the protocol. * Moderate to severe dry eye that would affect study measurements. * Other protocol-specified exclusion criteria may apply.

Contact & Investigator

Central Contact

Alcon Call Center

✉ alcon.medinfo@alcon.com

📞 1-888-451-3937

Principal Investigator

Clinical Trial Lead, Surgical

STUDY DIRECTOR

Alcon Research, LLC

Frequently Asked Questions

Who can join the NCT07502456 clinical trial?

This trial is open to participants of all sexes, aged 22 Years or older, studying Aphakia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07502456 currently recruiting?

Yes, NCT07502456 is actively recruiting participants. Contact the research team at alcon.medinfo@alcon.com for enrollment information.

Where is the NCT07502456 trial being conducted?

This trial is being conducted at Phoenix, United States, Brecksville, United States, Mt. Pleasant, United States, Sugar Land, United States and 1 additional location.

Who is sponsoring the NCT07502456 clinical trial?

NCT07502456 is sponsored by Alcon Research. The principal investigator is Clinical Trial Lead, Surgical at Alcon Research, LLC. The trial plans to enroll 122 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology